Prescription digital therapeutics startup MedRhythms has entered into a licensing agreement with Biogen to develop and commercialize its MR-004 product, which aims to improve mobility for people with multiple sclerosis (MS).
Under the deal, MedRhythms would receive a $3 million upfront payment from Biogen, with the potential to earn up to $117.5 million if certain development and commercial...
International pharma Boehringer Ingelheim and prescription digital therapeutics company Click Therapeutics have inked a $500 million-plus deal to jointly develop and commercialize a digital treatment for patients with schizophrenia.
The treatment, referred to as CT-155, will be a mobile app built on Click's proprietary tech platform, the companies said.
Employing cognitive and neurobehavioral...
